



## IMRICOR PERFORMS WORLD'S FIRST PFA ABLATION IN THE iCMR

**20 October 2025** – Melbourne, Australia (**19 September 2025** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc. (Company or Imricor) (ASX: IMR)**, is pleased to announce the completion of the first Pulsed Field Ablation (PFA) ever performed under real-time MRI guidance in an iCMR lab.

### Background

Pulsed Field Ablation has emerged as a promising new energy source for the treatment of atrial fibrillation (AF). While clinical data to date do not yet demonstrate superior efficacy over conventional radiofrequency (RF) ablation, PFA has shown important efficiency and safety advantages.

Imricor's technology enables real-time **MRI-guided cardiac ablation**, allowing physicians to perform procedures with *real-time visualization* of cardiac tissue and eliminating exposure to ionising radiation. This provides physicians and medical staff access to the gold-standard soft-tissue imaging modality to **plan, execute, and validate** each procedure while the patient remains on the table.

Atrial fibrillation ablations represent approximately **65–70% of all cardiac ablation procedures worldwide**<sup>1</sup>, and industry estimates suggest PFA could eventually account for **50–60% of this market**<sup>2</sup>. While RF ablation will continue to play a key role, Imricor remains committed to enabling MRI-guided procedures **regardless of energy source**, ensuring that physicians and patients benefit from the unique advantages of MRI-guided electrophysiology.

### World-First Achievement

Imricor performed the world's first in vivo PFA ablation **in the ventricle under real-time MRI guidance**, marking a significant step forward in the Company's PFA development program.

The pre-clinical animal study procedure was performed using the **second-generation Vision-MR™ Ablation Catheter** at Imricor's iCMR Design Centre, validating the Company's proprietary technology for integrating PFA energy with real-time MRI visualisation.

**Imricor's Chair and CEO, Steve Wedan, commented:** "This achievement represents another global breakthrough for Imricor and an important step toward our long-term vision **of performing all electrophysiology procedures** under real-time MRI guidance. This first PFA procedure demonstrates the flexibility and adaptability of our platform, positioning Imricor to serve the evolving needs of electrophysiologists worldwide and to deliver the benefits of real-time MRI guidance regardless of the energy source used for ablating."

---

<sup>1</sup> Cheng et al. (2024)

<sup>2</sup> Boston Scientific 2025 Investor Presentation



## ENDS

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

### Media and Investor Relations Contacts:

Simon Hinsley  
Executive Director, NWR  
simon@nwrcommunications.com.au  
+61 401 909 653

Nick Corkill  
VP Corporate Strategy, Imricor  
nick.corkill@imricor.com  
+61 450 475 633

### About Imricor

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

### Imricor's Products

Imricor is a pioneer and leader in developing MRI-compatible products for cardiac catheter ablation procedures, and it is the first company in the world to bring commercially viable and safe MRI-compatible products to the cardiac catheter ablation market.

The Vision-MR Ablation Catheter is the Company's prime product offering, specifically designed to work under real-time MRI guidance, with the intent of enabling higher success rates along with a faster and safer treatment compared to conventional procedures using x-ray guided catheters. The Vision-MR Ablation Catheter has been approved in the European Union, the Kingdom of Saudi Arabia (KSA), and New Zealand with an indication for treating type 1 atrial flutter. Imricor intends to seek approval for expanded indications in the future. The Company is also pursuing the required regulatory approvals to place its key products on the market in the U.S. and the other Middle East countries.

The Company has also obtained approval within the EU for the sale of its NorthStar 3D Mapping System, the Advantage-MR EP Recorder/Stimulator System and other consumable products, such as the Vision-MR Diagnostic Catheter and Vision-MR Dispersive Electrode.

Imricor sells its capital and consumable products to hospitals and clinics for use in Interventional Cardiac Magnetic Resonance Imaging (iCMR) labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed. An iCMR lab is an interventional lab that is fitted with MRI equipment for use in cardiac diagnostic and interventional procedures. The installation of iCMR labs is driven primarily by MRI equipment vendors working collaboratively with Imricor. Vendors such as Koninklijke Philips N.V., Siemens Healthcare GmbH, and GE HealthCare help to target certain sites and support the design and construction of iCMR labs for those sites.

### Foreign Ownership Restrictions

Imricor's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (ASX). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

### Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address



operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For personal use only